Morgan Stanley Dice Therapeutics, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$25.86 - $46.71 $13.5 Million - $24.4 Million	521,832 Added 672.14%	599,469 $27.9 Million
Q1 2023 May 15, 2023	SELL	$26.05 - $32.31 $166,407 - $206,396	-6,388 Reduced 7.6%	77,637 $2.22 Million
Q4 2022 Feb 14, 2023	BUY	$19.77 - $42.23 $908,787 - $1.94 Million	45,968 Added 120.79%	84,025 $2.62 Million
Q3 2022 Nov 14, 2022	BUY	$14.97 - $22.65 $87,379 - $132,208	5,837 Added 18.12%	38,057 $771,000
Q2 2022 Oct 27, 2022	BUY	$13.19 - $22.1 $389,724 - $652,988	29,547 Added 1105.39%	32,220 $500,000
Q2 2022 Aug 15, 2022	BUY	$13.19 - $22.1 $389,724 - $652,988	29,547 Added 1105.39%	32,220 $500,000
Q1 2022 Oct 27, 2022	SELL	$14.54 - $25.02 $429,613 - $739,265	-29,547 Reduced 91.7%	2,673 $51,000
Q1 2022 May 13, 2022	SELL	$14.54 - $25.02 $434,135 - $747,047	-29,858 Reduced 91.78%	2,673 $51,000
Q4 2021 Feb 14, 2022	BUY	$22.41 - $37.54 $729,019 - $1.22 Million	32,531 New	32,531 $823,000

17.7K

13K

Ticker DICE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,430,000
Description
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lea...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.